Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases Pharmaceutical Investing
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates Pharmaceutical Investing
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, HNST and HYZN Pharmaceutical Investing
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units Pharmaceutical Investing
OPDIVO® Receives Two New Health Canada Approvals for: Use with Chemotherapy for the Treatment for Patients with HER2 Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma Cancers; Use as Monotherapy for the Adjuvant Treatment for Patients with Completely Resected Esophageal or Gastroesophageal Junction Cancers Pharmaceutical Investing
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors Life Science Investing
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, HEPS, HMLP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Pharmaceutical Investing
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS for the Treatment of Lupus Nephritis Pharmaceutical Investing
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol Cannabis Investing News
